← Back to screener

AVANOS MEDICAL, INC. AVNS

Rank #1352 · NYSE · $1.2B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
49.6
P/E
-18.9
P/B
0.90
ROE
-4.8%
Op. Margin
0.6%
Debt Ratio
25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Average

P/E -18.9x, P/B 0.90x. Ranks in the top 46% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -4.8%. Ranks in the top 72% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 25%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★★☆☆☆
Weak

Revenue decline of 1.6% year over year. Ranks in the top 68% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014–$0.2B$0.2B$2.0B–20
2015–$0.2B$0.2B$2.1B–50
2016–$0.1B$0.0B$2.1B–45
2017–$-0.1B$-0.4B$1.5B–65
2018$0.6B$-0.1B$0.0B$1.1B-18.993
2019$0.6B$-0.0B$0.1B$1.1B-7.049
2020$0.7B$0.0B$0.1B$1.2B0.144
2021$0.7B$-0.1B$-0.0B$1.3B-8.032
2022$0.7B$-0.0B$-0.0B$1.3B-6.826
2023$0.6B$-0.0B$0.0B$1.3B-6.639
2024$0.7B$0.0B$0.1B$1.3B5.236
2025$0.7B$0.0B$-0.1B$1.3B0.625

← See the full screener